FDA Flags Misleading Claims for Cancer Drug by Biotech Billionaire Patrick Soon-Shiong
Federal health officials have issued a stern warning concerning controversial statements made by biotech billionaire Dr. Patrick Soon-Shiong regarding one of his company's cancer drugs. The Food and Drug Administration (FDA) raised alarms on Tuesday over misleading promotional content that could create false impressions about the medication's capabilities.
Warning Targets Podcast and Television Advertisement
The FDA's warning letter specifically addresses a television commercial and a separate podcast episode promoting Anktiva, the flagship product of ImmunityBio Inc. This biotech firm is among several acquired by Soon-Shiong, who also holds ownership of the Los Angeles Times newspaper. Following the publication of the FDA warning online, company shares experienced a dramatic decline, plummeting more than 24% during Tuesday's trading session.
Anktiva received FDA approval in 2024 for treating a particularly challenging form of bladder cancer. ImmunityBio has been actively pursuing regulatory approval to expand the drug's application to various other conditions, including specific types of lung and pancreatic cancer. However, the recent promotional activities have drawn significant regulatory scrutiny.
Controversial Statements During Podcast Interview
Soon-Shiong's problematic statements emerged during a January episode of The Sean Spicer Show podcast, which carried the provocative title: "Is the FDA blocking life-saving cancer treatments?" During the interview, the billionaire executive chairman and chief medical officer made several extraordinary claims about his company's pharmaceutical product.
At one point in the conversation, Soon-Shiong described Anktiva as "the most important molecule that could cure cancer." Minutes later, he asserted that while the drug currently holds approval for bladder cancer treatment, "it actually can treat all cancers." The executive further claimed during the same episode: "We have the therapy to prevent cancer if you were exposed to radiation, and that's Anktiva."
Regulatory Violations and Required Corrections
FDA regulators determined these statements violate federal drug marketing regulations because they "create a misleading impression" of the medication's actual capabilities and approved uses. Regulators additionally noted the podcast failed to include any information about potential risks and side effects associated with the drug, which can include urinary tract infections, pain, chills, and pyrexia.
Under established FDA law, all drug promotions must present a balanced perspective that includes both potential benefits and known risks. The regulatory warning, formally addressed to ImmunityBio CEO Richard Adcock, expresses similar concerns regarding a television advertisement for Anktiva. Both promotional materials referred to the company's drug as a "cancer vaccine," which FDA officials have categorically stated is inaccurate and misleading.
The FDA letter provides the company with fifteen days to correct these violations and submit a written response detailing their corrective action plan. By Tuesday afternoon, ImmunityBio had already removed the podcast link from their official website, indicating initial compliance with regulatory concerns.
Company Response and Regulatory Context
Sarah Singleton, spokesperson for the Culver City, California-based ImmunityBio, communicated via email that the company takes the FDA's warning "very seriously" and intends to "work cooperatively with the agency to address the matters raised in the letter." This regulatory action occurs within a broader context of increased FDA enforcement against pharmaceutical manufacturers during the current administration, including heightened scrutiny of executive appearances on television programs and podcast platforms.
The regulatory intervention highlights ongoing tensions between innovative biotech companies seeking to promote their products and federal agencies responsible for ensuring accurate, evidence-based information reaches healthcare providers and patients. As drug development accelerates in competitive markets, regulatory oversight remains crucial for maintaining scientific integrity and protecting public health interests.
